Medical technology company Integer Holdings (NYSE: ITGR) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 5% year on year to $472.1 million. The company expects the full year’s revenue to be around $1.85 billion, close to analysts’ estimates. Its non-GAAP profit of $1.76 per share was 3.6% above analysts’ consensus estimates.

Is now the time to buy ITGR? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Integer Holdings saw a positive market reaction to its fourth quarter results, as revenue and non-GAAP earnings per share both exceeded Wall Street expectations. Management cited strong performance in the Cardio & Vascular segment, particularly from acquisitions and demand in neurovascular, as a primary driver. CEO Peyman Khales emphasized the role of operational improvements and disciplined expense management, noting, "Operational improvements accounted for $30 million, or $0.86 per share, and reflected the benefits of higher sales volume, manufacturing efficiencies, operating expense management, and acquisition performance." The company’s product development pipeline and recent investments in manufacturing were also highlighted as contributors to the quarter's results.

Looking ahead, Integer Holdings’ guidance is shaped by temporary headwinds from three new products with lower-than-expected market adoption, but management stressed confidence in the underlying business and future growth trajectory. CEO Peyman Khales explained that, excluding these products, the core portfolio is expected to grow in line with market rates, supported by a robust product pipeline and investments in high-growth areas like electrophysiology and neuromodulation. CFO Diron Smith added that operating margins are expected to improve in the second half of the year as sales recover, while free cash flow generation remains a priority. Khales summed up, "We remain confident in our ability to return to 200 basis points above market organic growth in 2027."

Key Insights from Management’s Remarks

Management attributed the quarter’s revenue and margin performance to strong Cardio & Vascular momentum, recent acquisitions, and operational execution, while acknowledging short-term pressures from select new products.

• Cardio & Vascular segment strength: Growth in this area was driven by the Precision Coatings and VSI Parylene acquisitions, as well as heightened demand in neurovascular applications, supporting overall sales and margin gains.
• Impact of new product headwinds: Three recently launched products—two in electrophysiology and one in neuromodulation—experienced lower adoption rates, creating a 3% to 4% headwind on organic growth that management expects to be temporary.
• Operational improvements: Manufacturing efficiencies, particularly through the Integer Production System, contributed to margin expansion and cost containment, allowing adjusted operating margin to grow despite modest revenue gains.
• Capital management discipline: Integer Holdings repurchased $50 million in stock during the quarter and announced a $50 million accelerated share repurchase, reflecting ongoing capital allocation aimed at long-term shareholder value.
• Pipeline and development sales momentum: Product development sales, seen as a leading indicator for future growth, have increased 300% since 2017, with 80% of these efforts focused on high-growth markets like neurovascular and structural heart therapies.

Drivers of Future Performance

Management expects near-term sales growth to be constrained by lower adoption of select new products, but highlights a strong underlying business, operational investments, and a robust pipeline as key drivers for recovery and margin expansion in the coming year.

• Temporary product adoption headwinds: The sales outlook for 2026 is impacted by three new products with slower-than-expected market uptake. Management believes these headwinds are short-term and that once lapped, the company’s organic growth rate should return to outperforming the market by 2027.
• Pipeline-driven recovery: A diversified portfolio of new product launches, especially in high-growth segments like electrophysiology and neuromodulation, is expected to support sales acceleration in the second half of the year and beyond.
• Margin and cash flow focus: Management is not making structural cost cuts in response to short-term pressures, instead emphasizing operational efficiency and the Integer Production System. Operating margins are expected to recover as sales volumes improve, and free cash flow generation remains a priority.

Catalysts in Upcoming Quarters

The StockStory team will be watching (1) the pace at which new product adoption recovers after recent headwinds, (2) the impact of pipeline launches in high-growth markets like electrophysiology and neuromodulation, and (3) the company’s ability to expand margins as sales stabilize and operational improvements take hold. Execution on the accelerated ERP modernization and facility expansions will also be key signposts for long-term scalability.

Integer Holdings currently trades at $78.61, down from $86.48 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).

Now Could Be The Perfect Time To Invest In These Stocks

The market’s up big this year - but there’s a catch. Just 4 stocks account for half the S&P 500’s entire gain. That kind of concentration makes investors nervous, and for good reason. While everyone piles into the same crowded names, smart investors are hunting quality where no one’s looking - and paying a fraction of the price. Check out the high-quality names we’ve flagged in our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.